Merck & Co. Inc

FDA Regulatory Profile

Merck & Co. Inc appears in FDA public data with 5 recalls, 0 510(k) clearances, 27 FDA inspections, and 1 compliance action on record. Its most recent recall (D-0584-2025, Class II) was initiated on July 21, 2025.

Summary

Total Recalls
5
510(k) Clearances
0
Inspections
27
Compliance Actions
1

Recent Recalls

NumberClassProductDate
D-0584-2025Class IIBelsomra (suvorexant) tablets, 10mg, 30 Tablets in 3 Blister Cards per Carton, Each Blister Card conJuly 21, 2025
D-1310-2014Class IIILiptruzet (ezetimibe and atorvastin) tablets,10 mg/20 mg, a) 30 count blister (NDC 66582-321-30),January 13, 2014
D-1309-2014Class IIILiptruzet (ezetimibe and atorvastin) tablets,10 mg/10 mg, a) 30 count blister (NDC 66582-320-30),January 13, 2014
D-1312-2014Class IIILiptruzet (ezetimibe and atorvastin) tablets,10 mg/80 mg, a) 30 count blister (NDC 66582-323-30),January 13, 2014
D-1311-2014Class IIILiptruzet (ezetimibe and atorvastin) tablets,10 mg/40 mg, a) 30 count blister (NDC 66582-322-30),January 13, 2014